title: Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.
abstract: Two types of mutations of a transcription factor CCAAT-enhancer binding protein α (C/EBPα) are found in leukemic cells of 5%-14% of acute myeloid leukemia (AML) patients: N-terminal mutations expressing dominant negative p30 and C-terminal mutations in the basic leucine zipper domain. Our results showed that a mutation of C/EBPα in one allele was observed in AML after myelodysplastic syndrome, while the 2 alleles are mutated in de novo AML. Unlike an N-terminal frame-shift mutant (C/EBPα-N(m))-transduced cells, a C-terminal mutant (C/EBPα-C(m))-transduced cells alone induced AML with leukopenia in mice 4-12 months after bone marrow transplantation. Coexpression of both mutants induced AML with marked leukocytosis with shorter latencies. Interestingly, C/EBPα-C(m) collaborated with an Flt3-activating mutant Flt3-ITD in inducing AML. Moreover, C/EBPα-C(m) strongly blocked myeloid differentiation of 32Dcl3 cells, suggesting its class II mutation-like role in leukemogenesis. Although C/EBPα-C(m) failed to inhibit transcriptional activity of wild-type C/EBPα, it suppressed the synergistic effect between C/EBPα and PU.1. On the other hand, C/EBPα-N(m) inhibited C/EBPα activation in the absence of PU.1, despite low expression levels of p30 protein generated by C/EBPα-N(m). Thus, 2 types of C/EBPα mutations are implicated in leukemo-genesis, involving different and cooperating molecular mechanisms.
authors.affiliation: Division of Cellular Therapy, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
authors.forename: Naoko
authors.initials: N
authors.lastname: Kato
authors.forename: Jiro
authors.initials: J
authors.lastname: Kitaura
authors.forename: Noriko
authors.initials: N
authors.lastname: Doki
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Komeno
authors.forename: Naoko
authors.initials: N
authors.lastname: Watanabe-Okochi
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Togami
authors.forename: Fumio
authors.initials: F
authors.lastname: Nakahara
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Oki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Enomoto
authors.forename: Yumi
authors.initials: Y
authors.lastname: Fukuchi
authors.forename: Hideaki
authors.initials: H
authors.lastname: Nakajima
authors.forename: Yuka
authors.initials: Y
authors.lastname: Harada
authors.forename: Hironori
authors.initials: H
authors.lastname: Harada
authors.forename: Toshio
authors.initials: T
authors.lastname: Kitamura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D017209:Apoptosis; D015153:Blotting, Western; D016026:Bone Marrow Transplantation; D022763:CCAAT-Enhancer-Binding Protein-alpha / Q000235:genetics* / Q000378:metabolism; D002454:Cell Differentiation; D049109:Cell Proliferation; D004195:Disease Models, Animal; D024202:Electrophoretic Mobility Shift Assay; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000209:etiology* / Q000473:pathology* / Q000628:therapy; D008156:Luciferases / Q000378:metabolism; D008297:Male; D051379:Mice; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D009190:Myelodysplastic Syndromes / Q000209:etiology* / Q000473:pathology* / Q000628:therapy; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D012333:RNA, Messenger / Q000235:genetics; D015996:Survival Rate; D015533:Transcriptional Activation
chemical_list: D022763:CCAAT-Enhancer-Binding Protein-alpha; D012333:RNA, Messenger; D008156:Luciferases